research Enhanced Skin Permeation and Controlled Release of β-Sitosterol Using Cubosomes Encrusted with Dissolving Microneedles for the Management of Alopecia
The new delivery system improved hair growth in alopecia treatment.
Search
for
Sort by
Research
990-1000 / 1000+ resultsresearch Alpha Blockers and Finasteride for BPH-1996
research FOCAL HYPERTRICHOSIS DURING TOPICAL TACROLIMUS THERAPY FOR CHILDHOOD VITILIGO
An 8-year-old girl with vitiligo developed extra hair growth on her knee after using tacrolimus ointment.
research Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies
Patients and clinicians generally agree on eyebrow and eyelash hair loss improvements in severe alopecia areata.
research NANOCARRIER-BASED DELIVERY OF MINOXIDIL: CURRENT PERSPECTIVES AND FUTURE DIRECTIONS IN ALOPECIA THERAPY
Androgenetic alopecia (AGA) is a common genetic condition affecting the scalp, caused by the conversion of testosterone to Dihydrotestosterone (DHT) by the enzyme 5-Alpha Reductase, leading to hair follicle shrinkage. Current FDA-approved treatments, finasteride and minoxidil, have limitations, prompting research into nanocarrier-based drug delivery systems like liposomes, solid lipid nanoparticles, and transferosomes. These systems offer improved drug stability, targeted delivery, and sustained release while minimizing systemic exposure. Innovations such as antioxidant formulations and spironolactone-loaded nanoparticles aim to reduce oxidative stress and block androgen receptors. Despite promising preclinical outcomes, challenges remain in clinical translation, including the need for reliable trials, funding, and regulatory approval. The review highlights the importance of clinical validation and scalable production to harness nanotechnology's potential for AGA treatment.
research Comparison of a gonadotropin-releasing hormone agonist and a low dose oral contraceptive given alone or together in the treatment of hirsutism.
Combining a GnRH agonist with a low-dose oral contraceptive is more effective and safer for treating hirsutism than using either alone.
research NANOCARRIER-BASED DELIVERY OF MINOXIDIL: CURRENT PERSPECTIVES AND FUTURE DIRECTIONS IN ALOPECIA THERAPY
Androgenetic alopecia (AGA) is a common genetic condition affecting the scalp, caused by the conversion of testosterone to Dihydrotestosterone (DHT) by the enzyme 5-Alpha Reductase, leading to hair follicle shrinkage. Current FDA-approved treatments, finasteride and minoxidil, have limitations, prompting research into nanocarrier-based drug delivery systems like liposomes, solid lipid nanoparticles, and transferosomes. These systems offer improved drug stability, targeted delivery, and sustained release while minimizing systemic exposure. Innovations such as antioxidant formulations and spironolactone-loaded nanoparticles aim to reduce oxidative stress and block androgen receptors. Although preclinical results are promising, challenges remain in clinical translation, including the need for reliable trials, funding, and regulatory approval. The review highlights the importance of clinical validation and scalable production to harness nanotechnology's potential for AGA treatment.
research Prostaglandin D2(PGD2); prostaglandin D2 receptor (CRTH2; GPR44; CD294); prostaglandin D2 synthase (PTGDS)
Blocking a protein called prostaglandin D2 might help treat hair loss.
research Excimer Light versus Combination of Tacrolimus and Excimer Light in the Treatment of Alopecia Areata
Combining tacrolimus with excimer light is more effective for treating alopecia areata than using excimer light alone.
research Metoprolol
Metoprolol and propranolol may cause hair loss.